Drug intelligence / Profile preview

alpha-methyltryptophan

Development stage
Unknown
Lead developer
Medical College of Georgia
Modality
Small Molecules
Administration
Intravenous, Oral
01

Overview

Alpha-methyltryptophan is a synthetic tryptophan derivative that acts as a selective blocker of the amino acid transporter SLC6A14 (ATB0,+) and an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1). By blocking SLC6A14, alpha-methyltryptophan induces amino acid starvation, leading to decreased mTOR signaling, autophagy, and apoptosis in SLC6A14-positive cancer cells, such as estrogen receptor (ER)-positive breast cancer and colon cancer. Additionally, alpha-methyltryptophan has been shown to function as an effective weight-loss agent in animal models of obesity and metabolic syndrome. In its radiolabeled form, carbon C 11 alpha-methyltryptophan ([11C]AMT), it is utilized as a positron emission tomography (PET) imaging tracer to assess serotonin synthesis and monitor brain tumors, neuroendocrine neoplasms, and melanoma.

Other names
11C-AMT11C-alpha-methyltryptophanALTAMTAMTPalpha-methyl-DL-tryptophanalpha-methyl-L-tryptophanalpha-methyl-tryptophancarbon C 11 alpha-methyltryptophanα-MLTα-MTPα-methyl-DL-tryptophanα-methyl-L-tryptophanα-methyltryptophanαMTP
02

Targets

IDO1 (Indoleamine 2,3-dioxygenase 1)SLC1A5 (Alanine/serine/cysteine transporter 2)

Beyond the preview

Go deeper on alpha-methyltryptophan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alpha-methyltryptophan.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call